| PERIOD ENDING | 31-Mar-08 | 31-Mar-07 |
| Total Revenue |
-
|
-
|
| Cost of Revenue |
-
|
-
|
|
| Gross Profit |
-
|
-
|
|
| Operating Expenses |
| Research Development | 183 | 141 |
| Selling General and Administrative | 706 | 439 |
| Non Recurring |
-
|
-
|
| Others |
-
|
-
|
| |
| Total Operating Expenses |
-
|
-
|
|
|
| Operating Income or Loss | (890) | (581) |
|
| Income from Continuing Operations |
| Total Other Income/Expenses Net |
-
|
-
|
| Earnings Before Interest And Taxes | (890) | (581) |
| Interest Expense | 109 | 65 |
| Income Before Tax | (998) | (645) |
| Income Tax Expense |
-
| 2 |
| Minority Interest |
-
|
-
|
| |
| Net Income From Continuing Ops | (998) | (647) |
|
| Non-recurring Events |
| Discontinued Operations |
-
|
-
|
| Extraordinary Items |
-
|
-
|
| Effect Of Accounting Changes |
-
|
-
|
| Other Items |
-
|
-
|
|
|
| Net Income | (998) | (647) |
| Preferred Stock And Other Adjustments |
-
|
-
|
|
| Net Income Applicable To Common Shares | ($998) | ($647) |
0.01% Nasdaq 
Income Statement
